Reducing eclampsia-related deaths—a call to action

Langer, Ana; Villar, José; Tell, Katie; Kim, Theresa; Kennedy, Stephen

doi:10.1016/s0140-6736(08)60321-9

Cited by 48 publications

(43 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent article5 indicates that in poorly resourced countries, the availability of MgS0 4 and the lack of clinical protocols of management are significant issues associated with maternal deaths due to pre-eclampsia 5. In South Africa, these factors should not be issues, as MgS0 4 is widely available and is on the essential drug list for use at all health facilities.…”

Section: Discussionmentioning

confidence: 99%

Maternal deaths associated with hypertension in South Africa : lessons to learn from the Saving Mothers report, 2005-2007

Moodley

2011

CardioVascular Journal of Africa

View full text Add to dashboard Cite

SummaryFrom 2005–2007, there were 622 deaths associated with hypertensive disorders of pregnancy. Eclampsia was the major cause of death (n = 344; 55.3%). There were 173 (28.3%) deaths due to pre-eclampsia, and 38 (6.1%) associated with chronic hypertension. Cerebral complications were the final cause of death in 283 (45.5%), while cardiac failure and respiratory failure were the final causes in 142 (22.8%) and 158 (25.4%), respectively.Major problems were identified in all areas of assessment. Non-attendance for antenatal care (n = 106; 19.4%) and delay in seeking help (n = 106; 19.4%) were major patient-related factors. Communication problems (n = 63; 10.8%) and lack of facilities (n = 50; 8.5%) were health administration issues. Health worker-avoidable factors included problem recognition, delay in referral and management at an inappropriate level of healthcare.Compared to the previous report of 2002–2004, there was a reduction in deaths due to hypertension.

show abstract

Section: Discussionmentioning

confidence: 99%

Maternal deaths associated with hypertension in South Africa : lessons to learn from the Saving Mothers report, 2005-2007

Moodley

2011

CardioVascular Journal of Africa

View full text Add to dashboard Cite

show abstract

“…In under-resourced countries, the availability of MgSO 4 and the lack of protocols of management are significant issues associated with maternal deaths due to pre-eclampsia. 4,5 In South Africa these factors should not be issues, as MgSO 4 is widely available and on the essential drugs list for level 1 health facilities (district hospitals and clinics). Clinical guidelines for management of HDP, and in particular the management of obstetric emergencies, 6,7 have been widely distributed to all hospitals and clinics, but are perhaps not reaching all health professionals.…”

Section: Discussionmentioning

confidence: 99%

Maternal deaths associated with eclampsia in South Africa: Lessons to learn from the confidential enquiries into maternal deaths, 2005 - 2007

Moodley

2010

S Afr Med J

View full text Add to dashboard Cite

“…These included the lack of guidelines on its use, non-inclusion in many national essential drug lists, the wrong perception that the drug is meant for use only at the highest level of facilities (such as those with intensive care facilities), lack of training of health workers on its use, little incentive for pharmaceutical companies to commercialize the drug, and ready availability of prepackaged forms of less effective drugs. [25] In Nigeria, MgSO 4 had remained a drug one read about but hardly saw. It was initially been produced by the drug-manufacturing unit of the University College Hospital, Ibadan, but this was not enough for the country.…”

Section: Mechanism Of Actionmentioning

confidence: 99%

The use of magnesium sulphate for the treatment of severe pre-eclampsia and eclampsia

Tukur

2009

Ann Afr Med

View full text Add to dashboard Cite

Background: Pre-eclampsia and eclampsia are important causes of maternal and perinatal morbidity and mortality in the developing countries. There is need to provide the most effective management to pre-eclamptic and eclamptic patients. There is now evidence that magnesium sulphate is the most effective anticonvulsant. Method: In this article, a literature review was made on the contribution of pre-eclampsia and eclampsia to maternal mortality and how it can be curtailed by the use of magnesium sulphate. Results: The drug is administered by the Pritchard or Zuspan regimen, although modifi cations in the two protocols have been reported. Conclusion: A Nigerian national protocol has been developed on its use. There is need for further training of health workers on how to use this important drug.

show abstract

Reducing eclampsia-related deaths—a call to action

Cited by 48 publications

References 7 publications

Maternal deaths associated with hypertension in South Africa : lessons to learn from the Saving Mothers report, 2005-2007

Maternal deaths associated with hypertension in South Africa : lessons to learn from the Saving Mothers report, 2005-2007

Maternal deaths associated with eclampsia in South Africa: Lessons to learn from the confidential enquiries into maternal deaths, 2005 - 2007

The use of magnesium sulphate for the treatment of severe pre-eclampsia and eclampsia

Contact Info

Product

Resources

About